Gastrointestinal Cancers

From nurse navigators to surgeons, clinical social workers and more, a patient with cancer often has a village of team members helping them achieve a smooth and successful treatment experience.

Communication, self-advocacy and having someone in your corner are all critical tools to bring to a cancer care visit, says an expert from MedStar Georgetown University Hospital.

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

The Food and Drug Administration gave clearance to Bold Therapeutics for a phase 1b/2a trial examining treatments for advanced GI cancers.

Aprepitant, palonosetron and dexamethasone curbed chemotherapy-induced nausea and vomiting in certain women with gastrointestinal cancers who were receiving FOLFIRI or FOLFOX regimens.

The indication for the PD-1 blocking antibody now includes adults with mismatch repair-deficient recurrent or advanced disease, adding to the previous indication of endometrial solid tumors.

On behalf of Hope for Stomach Cancer, Dr. Yanghee Woo speaks with CURE® about risk factors for gastric cancer and the alarming rise in cases in young adults.

Knowing they’ve inherited a genetic mutation for stomach or breast cancer gives patients the power to plan ahead.

The FDA’s recent approval of Keytruda in combination with trastuzumab and chemotherapy in the first-line setting is an exciting change for a group of patients with certain subtypes of stomach cancer, according to an expert.

As patients aged 65 or older receive a diagnosis of cancer, their treatment course and priorities may differ from their younger counterparts.

Opdivo was the first PD-1 inhibitor to show durable responses in patients with esophageal squamous cell carcinoma.

Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.

Opdivo was approved by the FDA for use if disease persisted after neoadjuvant chemoradiotherapy in these patients, which is “exciting news,” as patients would typically undergo surveillance when this occurred.

Based on findings from the KEYNOTE-811 trial, the FDA approved Keytruda for the treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and chemotherapy.

The FDA has approved the combination of Opdivo (nivolumab) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma, making it the first frontline immunotherapy agent approved in this space.

In clinical trials, Opdivo in combination with chemotherapy improved overall survival and progression-free survival compared to chemotherapy alone.

Theresa Germano sat down with HEAL® to discuss her journey with cancer, how her daughter became her hero and how listening to her body benefited her in the end.

The priority review will focus on retifanlimab for the treatment of certain adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who did not tolerate platinum-based chemotherapy. Currently, according to Incyte, there are no approved treatments for this patient population.

For patients with gastric/ gastroesophageal cancer, treatment with Bavencio after chemotherapy shows favorable safety, but no overall survival improvement.

The priority review will focus on Opdivo with chemotherapy for the treatment several gastrointestinal cancers, which has recently become a rising area in novel treatment development.

In an interview with CURE®, expert Martha Raymond explains the importance of clinical trials during the COVID-19 pandemic and how clinicians must find a way to help ease patients anxieties as they return to the clinic.

The Food and Drug Administration approved Enhertu to treat adults with locally advanced or metastatic HER2-positive gastroesophageal or gastric cancer who have previously received a trastuzumab-based treatment regimen.

The FDA granted a priority review to the supplemental biologics license application for the combination of Keytruda and chemotherapy for the firstline treatment of locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.

I am a nurse practitioner and a professor. But my best job was being a daughter and caregiver to the most wonderful mother anyone could ever have.

Join us for our Inaugural 1st Hope Webcast on surgical strategies for Stage IV stomach cancer.